 Home > Active Ingredient News > Blood System > Blood: Bentuximab combined with nivolumab to rescue the long-term prognosis of relapsed/refractory Hodgkin's lymphoma

Blood: Bentuximab combined with nivolumab to rescue the long-term prognosis of relapsed/refractory Hodgkin's lymphoma

 Last Update: 2021-08-26
 Source: Internet
 Author: User

Tags

1 16 guard

resin non toxic

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

About 10%-30% of patients with classic Hodgkin lymphoma (cHL) are refractory to initial treatment or relapse after standard treatment

Lymphoma stem cells

Phase 1-2 studies evaluated the combination of Bentuximab (BV) and Nivolumab (Nivo) as the primary rescue therapy for patients with relapsed/refractory (r/r) classic Hodgkin lymphoma (cHL) Effectiveness and safety

In the first and second parts, BV and Nivo are staggered in the first cycle, and BV and Nivo are given on the same day in the 2-4 cycle

PFS and OS

The objective response rate (ORR; n=91) was 85%, and 67% of patients achieved complete remission (CR)

The objective response rate (ORR; n=91) was 85%, of which 67% of patients achieved complete remission (CR), and the objective response rate (ORR; n=91) was 85%, of which 67% of patients achieved complete remission ( At a median follow-up of 34.

immunity

The results of the study showed that the long-term follow-up of BV and Nivo as the primary rescue program showed long-lasting efficacy and excellent progression-free survival (PFS), especially in patients who underwent transplantation directly after the end of the study treatment, and there was no additional Toxic reaction

The long-term follow-up of BV and Nivo as the primary rescue plan showed long-lasting efficacy and excellent progression-free survival (PFS), especially in patients who underwent transplantation directly after the end of the study treatment, and there was no additional toxicity.

Original source:

Ranjana H.

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.